10 abstract hits under "Ziopharm" at ASH Dec 4-8 Orlando - the largest and most important Hematology meeting in the world and of the yr.....including NK cell abstract....
Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies
Result Type: Paper
Number: 862
Presenter: Partow Kebriaei
Program: Oral and Poster Abstracts
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Relapse
Time and Location:
Monday, December 7, 2015: 4:30 PM-6:00 PM
Tangerine 2 (WF2) (Orange County Convention Center)
Search Result:
... allogeneic T cells appears to have contributed to immune reconstitution and control of opportunistic viral infection. Disclosures: Huls: Intrexon and Ziopharm: Employment , Equity Ownership . Singh: Intrexon andZiopharm: Equity Ownership , Patents & Royalties . Olivares: Intrexon and Ziopharm: ...
Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation
Result Type: Paper
Number: 152
Presenter: Sameh Gaballa
Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results II
Time and Location:
Saturday, December 5, 2015: 4:00 PM-5:30 PM
W304 (Orange County Convention Center)
Search Result:
... xCRp: Complete Remission with incomplete count recovery; **Patients had aplastic anemia. Figure 1: Disclosures: Brammer: Celgene: Research Funding . Lee: Ziopharm: Equity Ownership ; Cyto-Sen: Equity Ownership ; Intrexon: Equity Ownership . Rezvani: Pharmacyclics: Research Funding . Alousi: Therakos, Inc: Research ...
Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study
Result Type: Paper
Number: 929
Presenter: Nina Shah
Program: Oral and Poster Abstracts
Session: 731. Clinical Autologous Transplantation: Results III
Time and Location:
Monday, December 7, 2015: 6:15 PM-7:45 PM
W314 (Orange County Convention Center)
Search Result:
... , Research Funding ; Forma Therapeutics: Consultancy . Cooper: Intrexon: Equity Ownership , Patents & Royalties , Research Funding ; ZIOPHARM Oncology: Employment , Equity Ownership , Patents & Royalties , Research Funding . Lee: Cyto-Sen: Equity Ownership ; Ziopharm: Equity ...
Mitochondrial Biomass As a Measure of Fitness for T Cells Expressing Chimeric Antigen Receptors
Result Type: Paper
Number: 3242
Presenter: Bipulendu Jena
Program: Oral and Poster Abstracts
Session: 801. Gene Therapy and Transfer: Poster II
Time and Location:
Sunday, December 6, 2015: 6:00 PM-8:00 PM
Hall A (Orange County Convention Center)
Search Result:
... Center, Houston, TX2Department of Neurology, Baylor College of Medicine, Houston, TX3Pediatrics Research, University of Texas MD Anderson Cancer Center, Houston, TX4Ziopharm Oncology Inc., Boston, MA Anti-tumor efficacy of genetically modified T cells depends on in vivo expansion and durable persistence of ...
Use of Low Molecular Weight Heparin (LMWH) in Thrombocytopenic Patients with Hematologic Malignancy-Associated Venous Thromboembolism (VTE)
Result Type: Paper
Number: 3482
Presenter: Nabin Khanal
Program: Oral and Poster Abstracts
Session: 311. Disorders of Platelet Number or Function: Poster III
Time and Location:
Monday, December 7, 2015: 6:00 PM-8:00 PM
Hall A (Orange County Convention Center)
Search Result:
... Funding ; Incyte Corp: Research Funding ; Acerta Pharma: Research Funding ; GlaxoSmithKline: Research Funding . Armitage: Celgene: Consultancy ; Ziopharm: Consultancy ; Spectrum: Consultancy ; Roche: Consultancy ; GlaxoSmithKline: Consultancy , Membership on an entity?s Board of Directors or advisory ...
Clinical Impact of Internet-Based Tools to Help Guide Therapeutic Decisions for Mantle Cell Lymphoma (MCL)
Result Type: Paper
Number: 4527
Presenter: Kristen Rosenthal
Program: Oral and Poster Abstracts
Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster III
Time and Location:
Monday, December 7, 2015: 6:00 PM-8:00 PM
Hall A (Orange County Convention Center)
Search Result:
... of Directors or advisory committees ; Conatus: Consultancy , Membership on an entity?s Board of Directors or advisory committees ; Ziopharm: Consultancy . See more of: 902. Health Services and Outcomes Research ? Malignant Diseases: Poster III See more of: Health ...
Classification of Non-Hodgkin Lymphoma in Seven Geographic Regions Around the World: Review of 4539 Cases from the International Non-Hodgkin Lymphoma Classification Project
Result Type: Paper
Number: 1484
Presenter: Anamarija Perry
Program: Oral and Poster Abstracts
Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster I
Time and Location:
Saturday, December 5, 2015: 5:30 PM-7:30 PM
Hall A (Orange County Convention Center)
Search Result:
... are likely responsible, and more detailed epidemiologic studies are needed to better understand these differences. Disclosures: Armitage: Celgene: Consultancy ; Ziopharm: Consultancy ; Tesaro Bio, Inc: Membership on an entity?s Board of Directors or advisory committees ; GlaxoSmithKline: Consultancy , Membership ...
Phase I Trial of IL-21 Ex Vivo Expanded NK Cells Administration to Prevent Disease Relapse after Haploidentical Stem-Cell Transplantation for Myeloid Leukemias
Result Type: Paper
Number: 102
Presenter: Stefan Ciurea
Program: Oral and Poster Abstracts
Session: 703. Adoptive Immunotherapy: Clinical Studies
Time and Location:
Saturday, December 5, 2015: 12:00 PM-1:30 PM
W314 (Orange County Convention Center)
Search Result:
... JC 3x107 C2/C2, Bw4 Son C1/C2, Bw4 Yes A/B 2 Better Cen-A/B + NE Disclosures: Lee: Intrexon: Equity Ownership ; Ziopharm: Equity Ownership ; Cyto-sen: Equity Ownership . Rezvani: Pharmacyclics: Research Funding . See more of: 703. Adoptive Immunotherapy: Clinical Studies ...
Therapeutic Effects of ALT-803, an IL-15 Superagonist, in Combination with Anti-CD20 Chimeric Antigen Receptor Modified Expanded Natural Killer CELLS Against Pediatric Burkitt Lymphoma (BL)
Result Type: Paper
Number: 3085
Presenter: Yaya Chu
Program: Oral and Poster Abstracts
Session: 703. Adoptive Immunotherapy: Poster II
Time and Location:
Sunday, December 6, 2015: 6:00 PM-8:00 PM
Hall A (Orange County Convention Center)
Search Result:
... models is under investigation. Disclosures: Wong: Altor BioScience Corporation: Employment , Other: stockholder of Altor Bioscience Corporation . Lee: Intrexon, Ziopharm, Cyto-Sen: Equity Ownership . See more of: 703. Adoptive Immunotherapy: Poster II See more of: Adoptive Immunotherapy See more of: ...
801. Gene Therapy and Transfer: Poster II
Result Type: Session
Program: Oral and Poster Abstracts
Time and Location:
Sunday, December 6, 2015: 6:00 PM-8:00 PM
Hall A (Orange County Convention Center)
Search Result:
... Center, Houston, TX2Department of Neurology, Baylor College of Medicine, Houston, TX3Pediatrics Research, University of Texas MD Anderson Cancer Center, Houston, TX4Ziopharm Oncology Inc., Boston, MA 3243 Characterization of Lentiviral Vector Derived Anti-Bcma CAR T Cells Reveals Key Parameters for Robust Manufacturing ...
